The miRNA let-7a1 inhibits the expression of insulin-like growth factor 1 receptor (IGF1R) in prostate cancer PC-3 cells
Reduced microRNA (miRNA) let-7a expression and the activation of insulin-like growth factor-1 receptor (IGF1R) signalling are both involved in prostate cancer and progression. In the present study, we demonstrated that the growth inhibitory effect of let-7a1 is directly related to targeting IGF1R ge...
Saved in:
Published in | Asian journal of andrology Vol. 15; no. 6; pp. 753 - 758 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
China
Medknow Publications & Media Pvt. Ltd
01.11.2013
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Reduced microRNA (miRNA) let-7a expression and the activation of insulin-like growth factor-1 receptor (IGF1R) signalling are both involved in prostate cancer and progression. In the present study, we demonstrated that the growth inhibitory effect of let-7a1 is directly related to targeting IGF1R gene expression in PC-3 cells. TargetScan predicted three potential target sites (T1, T2 and T3) of let-7a in the 3' untranslational region (3' UTR) of IGF1R mRNA. Real-time PCR, Western blot and luciferase reporter assays were used to detect the effects of let-7a1 overexpression or let-7a1 inhibitor on the IGF1R gene expression in PC-3 cells. The results indicated that let-7a1 could inhibit IGF1R expression by directly targeting the T1 and T2 sites in the 3' UTR of the IGF1R mRNA. We then used RT-PCR, luciferase reporter assays, 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl-2H-tetrazolium bromide (MTT) assay, flow cytometry and Hoechst 33342 staining to examine whether let-7a1-mediated inhibition of IGF1R expression also affects the IGF1R-mediated signalling events, including Elk1 activity and c-fos gene expression, proliferation, apoptosis and cell cycle. We demonstrated that let-7a1-mediated IGF1R downregulation was accompanied by attenuation of Elk1 activity and c-fos expression, inhibition of cell proliferation, enhanced apoptosis and cell cycle arrest, and that loss function of let-7a1 via inhibition can upregulate IGF1R accompanied by an increase of Elk1 activity and c-fos expression, thereby enhancing cell proliferation. Altogether, these findings suggest that let-7a may be novel therapeutic candidate for prostate cancer. |
---|---|
AbstractList | Reduced microRNA (miRNA)
let-7a
expression and the activation of insulin-like growth factor-1 receptor (IGF1R) signalling are both involved in prostate cancer and progression. In the present study, we demonstrated that the growth inhibitory effect of
let-7a
1 is directly related to targeting
IGF1R
gene expression in PC-3 cells. TargetScan predicted three potential target sites (T1, T2 and T3) of
let-7a
in the 3′ untranslational region (3′ UTR) of
IGF1R
mRNA. Real-time PCR, Western blot and luciferase reporter assays were used to detect the effects of
let-7a
1 overexpression or
let-7a
1 inhibitor on the
IGF1R
gene expression in PC-3 cells. The results indicated that
let-7a
1 could inhibit
IGF1R
expression by directly targeting the T1 and T2 sites in the 3′ UTR of the
IGF1R
mRNA. We then used RT-PCR, luciferase reporter assays, 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl-2
H
-tetrazolium bromide (MTT) assay, flow cytometry and Hoechst 33342 staining to examine whether
let-7a
1-mediated inhibition of
IGF1R
expression also affects the IGF1R-mediated signalling events, including Elk1 activity and
c-fos
gene expression, proliferation, apoptosis and cell cycle. We demonstrated that
let-7a
1-mediated IGF1R downregulation was accompanied by attenuation of Elk1 activity and
c-fos
expression, inhibition of cell proliferation, enhanced apoptosis and cell cycle arrest, and that loss function of
let-7a
1
via
inhibition can upregulate IGF1R accompanied by an increase of Elk1 activity and
c-fos
expression, thereby enhancing cell proliferation. Altogether, these findings suggest that
let-7a
may be novel therapeutic candidate for prostate cancer. Reduced microRNA (miRNA) let-7a expression and the activation of insulin-like growth factor-1 receptor (IGF1R) signalling are both involved in prostate cancer and progression. In the present study, we demonstrated that the growth inhibitory effect of let-7a1 is directly related to targeting IGF1R gene expression in PC-3 cells. TargetScan predicted three potential target sites (T1, T2 and T3) of let-7a in the 3' untranslational region (3' UTR) of IGF1R mRNA. Real-time PCR, Western blot and luciferase reporter assays were used to detect the effects of let-7a1 overexpression or let-7a1 inhibitor on the IGF1R gene expression in PC-3 cells. The results indicated that let-7a1 could inhibit IGF1R expression by directly targeting the T1 and T2 sites in the 3' UTR of the IGF1R mRNA. We then used RT-PCR, luciferase reporter assays, 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl-2H-tetrazolium bromide (MTT) assay, flow cytometry and Hoechst 33342 staining to examine whether let-7a1-mediated inhibition of IGF1R expression also affects the IGF1R-mediated signalling events, including Elk1 activity and c-fos gene expression, proliferation, apoptosis and cell cycle. We demonstrated that let-7a1-mediated IGF1R downregulation was accompanied by attenuation of Elk1 activity and c-fos expression, inhibition of cell proliferation, enhanced apoptosis and cell cycle arrest, and that loss function of let-7a1 via inhibition can upregulate IGF1R accompanied by an increase of Elk1 activity and c-fos expression, thereby enhancing cell proliferation. Altogether, these findings suggest that let-7a may be novel therapeutic candidate for prostate cancer. Reduced microRNA (miRNA) let-7a expression and the activation of insulin-like growth factor-1 receptor (IGF1R) signalling are both involved in prostate cancer and progression. In the present study, we demonstrated that the growth inhibitory effect of let-7a1 is directly related to targeting IGF1R gene expression in PC-3 cells. TargetScan predicted three potential target sites (T1, T2 and T3) of let-7a in the 3' untranslational region (3' UTR) of IGF1R mRNA. Real-time PCR, Western blot and luciferase reporter assays were used to detect the effects of let-7a1 overexpression or let-7a1 inhibitor on the IGF1R gene expression in PC-3 cells. The results indicated that let-7a1 could inhibit IGF1R expression by directly targeting the T1 and T2 sites in the 3' UTR of the IGF1R mRNA. We then used RT-PCR, luciferase reporter assays, 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl-2H-tetrazolium bromide (MTT) assay, flow cytometry and Hoechst 33342 staining to examine whether let-7a1-mediated inhibition of IGF1R expression also affects the IGF1R-mediated signalling events, including Elk1 activity and c-fos gene expression, proliferation, apoptosis and cell cycle. We demonstrated that let-7a1-mediated IGF1R downregulation was accompanied by attenuation of Elk1 activity and c-fos expression, inhibition of cell proliferation, enhanced apoptosis and cell cycle arrest, and that loss function of let-7a1 via inhibition can upregulate IGF1R accompanied by an increase of Elk1 activity and c-fos expression, thereby enhancing cell proliferation. Altogether, these findings suggest that let-7a may be novel therapeutic candidate for prostate cancer.Reduced microRNA (miRNA) let-7a expression and the activation of insulin-like growth factor-1 receptor (IGF1R) signalling are both involved in prostate cancer and progression. In the present study, we demonstrated that the growth inhibitory effect of let-7a1 is directly related to targeting IGF1R gene expression in PC-3 cells. TargetScan predicted three potential target sites (T1, T2 and T3) of let-7a in the 3' untranslational region (3' UTR) of IGF1R mRNA. Real-time PCR, Western blot and luciferase reporter assays were used to detect the effects of let-7a1 overexpression or let-7a1 inhibitor on the IGF1R gene expression in PC-3 cells. The results indicated that let-7a1 could inhibit IGF1R expression by directly targeting the T1 and T2 sites in the 3' UTR of the IGF1R mRNA. We then used RT-PCR, luciferase reporter assays, 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl-2H-tetrazolium bromide (MTT) assay, flow cytometry and Hoechst 33342 staining to examine whether let-7a1-mediated inhibition of IGF1R expression also affects the IGF1R-mediated signalling events, including Elk1 activity and c-fos gene expression, proliferation, apoptosis and cell cycle. We demonstrated that let-7a1-mediated IGF1R downregulation was accompanied by attenuation of Elk1 activity and c-fos expression, inhibition of cell proliferation, enhanced apoptosis and cell cycle arrest, and that loss function of let-7a1 via inhibition can upregulate IGF1R accompanied by an increase of Elk1 activity and c-fos expression, thereby enhancing cell proliferation. Altogether, these findings suggest that let-7a may be novel therapeutic candidate for prostate cancer. |
Author | Chen, Wei-Wen Zhang, Ju Jiang, An-Li Liu, Chun-Yan Xue, Jing Wang, Li-Na Li, Chao-Yang Zhang, Peng-Ju |
Author_xml | – sequence: 1 givenname: Li-Na surname: Wang fullname: Wang, Li-Na – sequence: 2 givenname: Wei-Wen surname: Chen fullname: Chen, Wei-Wen – sequence: 3 givenname: Ju surname: Zhang fullname: Zhang, Ju – sequence: 4 givenname: Chao-Yang surname: Li fullname: Li, Chao-Yang – sequence: 5 givenname: Chun-Yan surname: Liu fullname: Liu, Chun-Yan – sequence: 6 givenname: Jing surname: Xue fullname: Xue, Jing – sequence: 7 givenname: Peng-Ju surname: Zhang fullname: Zhang, Peng-Ju – sequence: 8 givenname: An-Li surname: Jiang fullname: Jiang, An-Li |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23974362$$D View this record in MEDLINE/PubMed |
BookMark | eNptkd1rFDEUxYNU7Ic--S4BXyoyaz4nyYtQFlsLRaVU8C1ks3e6WWeTaTKj9b83Q2vR4lMu3F8O59xziPZiioDQS0oWlHD9zm3dghHKF1o8QQdUCdko1rK9OhOim1azb_vosJQtIYxTY56hfcaNErxlB-j2agN4Fy4_neAexkY5ikPchFUYCx7rCm6HDKWEFHHq6qpMfYhNH74Dvs7p57jBnfNjypjiDB6GeTw-Pzull28qjYecyuhGwN5FDxl_WTYce-j78hw97Vxf4MX9e4S-nn64Wn5sLj6fnS9PLhoviKmGlFFetkQB65wRThNJvJaatcR0SrZSd8p4t_aeyBUTlEhlRNdpMHRF1nrNj9D7O91hWu1g7SGO2fV2yGHn8i-bXLD_bmLY2Ov0w3ItBZGiChzfC-R0M0EZ7S6UOYKLkKZiqRCGKcMNrejrR-g2TTnWeDOlmSCa8kq9-tvRg5U_pVTg7R3g6_VKhu4BocTOldtauZ0rt3r2Rx_RPtST18ZqnND_989vbhCtRA |
CitedBy_id | crossref_primary_10_1038_cddiscovery_2017_28 crossref_primary_10_4103_1008_682X_123680 crossref_primary_10_1155_2015_358125 crossref_primary_10_2174_0122115366253242231020053221 crossref_primary_10_18632_oncotarget_4451 crossref_primary_10_1111_cas_12626 crossref_primary_10_1016_j_canlet_2017_08_011 crossref_primary_10_3390_molecules27030900 crossref_primary_10_1186_s43042_021_00190_9 crossref_primary_10_3390_cimb46120821 crossref_primary_10_1111_andr_12921 crossref_primary_10_1002_jgm_3016 crossref_primary_10_1007_s12032_014_0934_3 crossref_primary_10_1186_s12931_018_0805_0 crossref_primary_10_1016_j_cca_2015_09_022 |
Cites_doi | 10.1080/02841860902874748 10.1038/aja.2012.160 10.3322/caac.20073 10.1158/0008-5472.CAN-04-2446 10.1101/gr.082701.108 10.1677/ERC-08-0084 10.1016/j.molmed.2004.12.005 10.1371/journal.pone.0010147 10.3892/or.2012.2027 10.1016/j.bbrc.2011.11.119 10.1046/j.1464-410X.2003.04061.x 10.1158/0008-5472.CAN-08-1954 10.1016/j.cell.2009.03.047 10.1016/j.urolonc.2006.07.019 10.1016/j.cell.2010.05.017 10.1210/jc.2012-1929 10.1186/bcr3098 10.1158/0008-5472.CAN-04-0637 10.1007/978-3-540-37696-5_4 10.1038/nature06174 10.1007/s10549-010-1168-5 10.4161/cc.7.6.5834 10.1002/hep.23380 10.1101/gad.1640608 10.1089/cbr.2012.1307 10.1016/S0304-3835(03)00159-9 10.1016/j.lungcan.2007.07.013 |
ContentType | Journal Article |
Copyright | Copyright Nature Publishing Group Nov 2013 Copyright © 2013 SIMM & SJTU 2013 SIMM & SJTU |
Copyright_xml | – notice: Copyright Nature Publishing Group Nov 2013 – notice: Copyright © 2013 SIMM & SJTU 2013 SIMM & SJTU |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1038/aja.2013.84 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection (UHCL Subscription) Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest One Academic Middle East (New) MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | miRNA let-7a1 inhibits the expression of insulin-like growth factor 1 receptor |
EISSN | 1745-7262 |
EndPage | 758 |
ExternalDocumentID | PMC3854054 3116500401 23974362 10_1038_aja_2013_84 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -Q- 1OC 23N 2WC 36B 39C 4.4 53G 5GY 5VR 5VS 6J9 70F 7X7 88E 8FI 8FJ 8R4 8R5 AAYXX ABKZE ABUWG ACGFO ACGFS ACIHN AEAQA AENEX AFKRA AFUIB AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS BENPR BPHCQ BVXVI CCPQU CITATION CS3 DIK E3Z EBS EJD EMB EMOBN F5P FRP FYUFA GROUPED_DOAJ GX1 HMCUK HYE HZ~ IAO IHR JSO KQ8 M1P OK1 P2P P6G PHGZM PHGZT PQQKQ PROAC PSQYO Q2X RNTTT RPM SV3 TR2 U5O UKHRP W3E ~88 -05 -0E -SE -S~ .3N 31~ 8-1 92F 92I 92M 9D9 9DE AAOIN ACXQS ADJBI AFBPY AFZJQ AJAOE AZFZN BFHJK C1A CAG CAJEE CCEZO CGR CHBEP CIEJG CO8 COF CUY CVF CW9 DCZOG ECM EIF H13 IHW INH INR IPNFZ ITC JUIAU LH4 LW6 N8Y NPM OVD PJZUB PPXIY Q-- Q-4 RIG RMW RT5 S.. T8U TCJ TEORI TGQ U1F U1G U5E WFFXF ~N3 3V. 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c409t-7797c5607e2fa94a8050c8582609f75658f79cadcc05b24105794ff8e91b0d8d3 |
IEDL.DBID | 7X7 |
ISSN | 1008-682X 1745-7262 |
IngestDate | Thu Aug 21 18:20:29 EDT 2025 Thu Jul 10 22:11:57 EDT 2025 Fri Jul 25 23:36:35 EDT 2025 Mon Jul 21 05:57:02 EDT 2025 Sun Jul 06 05:09:19 EDT 2025 Thu Apr 24 22:58:27 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c409t-7797c5607e2fa94a8050c8582609f75658f79cadcc05b24105794ff8e91b0d8d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These authors contributed equally to this work. |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854054/pdf/aja201384a.pdf |
PMID | 23974362 |
PQID | 1448240813 |
PQPubID | 28679 |
PageCount | 6 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3854054 proquest_miscellaneous_1449279391 proquest_journals_1448240813 pubmed_primary_23974362 crossref_primary_10_1038_aja_2013_84 crossref_citationtrail_10_1038_aja_2013_84 |
PublicationCentury | 2000 |
PublicationDate | 2013-11-01 |
PublicationDateYYYYMMDD | 2013-11-01 |
PublicationDate_xml | – month: 11 year: 2013 text: 2013-11-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | China |
PublicationPlace_xml | – name: China – name: Shanghai |
PublicationTitle | Asian journal of andrology |
PublicationTitleAlternate | Asian J Androl |
PublicationYear | 2013 |
Publisher | Medknow Publications & Media Pvt. Ltd Nature Publishing Group |
Publisher_xml | – name: Medknow Publications & Media Pvt. Ltd – name: Nature Publishing Group |
References | Colamaio M (aja201384-bib21) 2012; 97 Martello G (aja201384-bib14) 2010; 141 Pollak M (aja201384-bib5) 2007; 174 LeRoith D (aja201384-bib6) 2003; 195 Nickerson T (aja201384-bib11) 2001; 61 Xiong Y (aja201384-bib17) 2010; 51 Morgan C (aja201384-bib2) 2009; 48 Papatsoris AG (aja201384-bib7) 2005; 11 Valastyan S (aja201384-bib16) 2009; 137 Armstrong AJ (aja201384-bib3) 2005; 12 Park SM (aja201384-bib18) 2008; 22 Zhu ML (aja201384-bib4) 2008; 15 Jemal A (aja201384-bib1) 2010; 60 Ryan CJ (aja201384-bib8) 2007; 25 Kim SJ (aja201384-bib22) 2012; 14 Cai K (aja201384-bib20) 2012; 28 Esquela-Kerscher A (aja201384-bib27) 2008; 7 Dong Q (aja201384-bib25) 2010; 5 Liu Y (aja201384-bib23) 2012; 417 Lu L (aja201384-bib24) 2011; 126 Yang N (aja201384-bib28) 2008; 68 Ma L (aja201384-bib13) 2007; 449 Hellawell GO (aja201384-bib9) 2003; 91 Friedman RC (aja201384-bib12) 2009; 19 Inamura K (aja201384-bib26) 2007; 58 Takamizawa J (aja201384-bib29) 2004; 64 Krueckl SL (aja201384-bib10) 2004; 64 Wang YY (aja201384-bib19) 2013; 28 Amankwah EK (aja201384-bib15) 2013; 15 18344688 - Cell Cycle. 2008 Mar 15;7(6):759-64 17349528 - Urol Oncol. 2007 Mar-Apr;25(2):134-40 20848182 - Breast Cancer Res Treat. 2011 Apr;126(3):687-94 23353719 - Asian J Androl. 2013 Mar;15(2):226-30 19925378 - Acta Oncol. 2009;48(6):882-9 17728006 - Lung Cancer. 2007 Dec;58(3):392-6 20418948 - PLoS One. 2010;5(4):e10147 15574769 - Cancer Res. 2004 Dec 1;64(23):8620-9 23134218 - Cancer Biother Radiopharm. 2013 Mar;28(2):131-7 18667687 - Endocr Relat Cancer. 2008 Dec;15(4):841-9 16018833 - Can J Urol. 2005 Jun;12 Suppl 2:42-7 20610543 - CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 11507082 - Cancer Res. 2001 Aug 15;61(16):6276-80 18955434 - Genome Res. 2009 Jan;19(1):92-105 12767520 - Cancer Lett. 2003 Jun 10;195(2):127-37 20603000 - Cell. 2010 Jun 25;141(7):1195-207 18381893 - Genes Dev. 2008 Apr 1;22(7):894-907 19524507 - Cell. 2009 Jun 12;137(6):1032-46 17898713 - Nature. 2007 Oct 11;449(7163):682-8 22251626 - Breast Cancer Res. 2012;14(1):R14 22965940 - J Clin Endocrinol Metab. 2012 Nov;97(11):E2168-78 15694866 - Trends Mol Med. 2005 Feb;11(2):52-5 20041405 - Hepatology. 2010 Mar;51(3):836-45 12581018 - BJU Int. 2003 Feb;91(3):271-7 15172979 - Cancer Res. 2004 Jun 1;64(11):3753-6 22155254 - Biochem Biophys Res Commun. 2012 Jan 6;417(1):371-5 22972404 - Oncol Rep. 2012 Dec;28(6):2101-6 17302184 - Recent Results Cancer Res. 2007;174:49-53 19074899 - Cancer Res. 2008 Dec 15;68(24):10307-14 |
References_xml | – volume: 48 start-page: 822 year: 2009 ident: aja201384-bib2 publication-title: Acta Oncol doi: 10.1080/02841860902874748 – volume: 15 start-page: 226 year: 2013 ident: aja201384-bib15 publication-title: Asian J Androl doi: 10.1038/aja.2012.160 – volume: 60 start-page: 277 year: 2010 ident: aja201384-bib1 publication-title: CA Cancer J Clin doi: 10.3322/caac.20073 – volume: 64 start-page: 8620 year: 2004 ident: aja201384-bib10 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-2446 – volume: 19 start-page: 92 year: 2009 ident: aja201384-bib12 publication-title: Genome Res doi: 10.1101/gr.082701.108 – volume: 15 start-page: 841 year: 2008 ident: aja201384-bib4 publication-title: Endocr Relat Cancer doi: 10.1677/ERC-08-0084 – volume: 12 start-page: 42 year: 2005 ident: aja201384-bib3 publication-title: Can J Urol – volume: 11 start-page: 52 year: 2005 ident: aja201384-bib7 publication-title: Trends Mol Med doi: 10.1016/j.molmed.2004.12.005 – volume: 5 start-page: e10147 year: 2010 ident: aja201384-bib25 publication-title: PLoS ONE doi: 10.1371/journal.pone.0010147 – volume: 28 start-page: 2101 year: 2012 ident: aja201384-bib20 publication-title: Oncol Rep doi: 10.3892/or.2012.2027 – volume: 417 start-page: 371 year: 2012 ident: aja201384-bib23 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2011.11.119 – volume: 91 start-page: 271 year: 2003 ident: aja201384-bib9 publication-title: BJU Int doi: 10.1046/j.1464-410X.2003.04061.x – volume: 68 start-page: 10307 year: 2008 ident: aja201384-bib28 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-1954 – volume: 137 start-page: 1032 year: 2009 ident: aja201384-bib16 publication-title: Cell doi: 10.1016/j.cell.2009.03.047 – volume: 25 start-page: 134 year: 2007 ident: aja201384-bib8 publication-title: Urol Oncol doi: 10.1016/j.urolonc.2006.07.019 – volume: 61 start-page: 6276 year: 2001 ident: aja201384-bib11 publication-title: Cancer Res – volume: 141 start-page: 1195 year: 2010 ident: aja201384-bib14 publication-title: Cell doi: 10.1016/j.cell.2010.05.017 – volume: 97 start-page: E2168 year: 2012 ident: aja201384-bib21 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2012-1929 – volume: 14 start-page: R14 year: 2012 ident: aja201384-bib22 publication-title: Breast Cancer Res doi: 10.1186/bcr3098 – volume: 64 start-page: 3753 year: 2004 ident: aja201384-bib29 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-0637 – volume: 174 start-page: 49 year: 2007 ident: aja201384-bib5 publication-title: Recent Results Cancer Res doi: 10.1007/978-3-540-37696-5_4 – volume: 449 start-page: 682 year: 2007 ident: aja201384-bib13 publication-title: Nature doi: 10.1038/nature06174 – volume: 126 start-page: 687 year: 2011 ident: aja201384-bib24 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-010-1168-5 – volume: 7 start-page: 759 year: 2008 ident: aja201384-bib27 publication-title: Cell Cycle doi: 10.4161/cc.7.6.5834 – volume: 51 start-page: 836 year: 2010 ident: aja201384-bib17 publication-title: Hepatology doi: 10.1002/hep.23380 – volume: 22 start-page: 894 year: 2008 ident: aja201384-bib18 publication-title: Genes Dev doi: 10.1101/gad.1640608 – volume: 28 start-page: 131 year: 2013 ident: aja201384-bib19 publication-title: Cancer Biother Radiopharm doi: 10.1089/cbr.2012.1307 – volume: 195 start-page: 127 year: 2003 ident: aja201384-bib6 publication-title: Cancer Lett doi: 10.1016/S0304-3835(03)00159-9 – volume: 58 start-page: 392 year: 2007 ident: aja201384-bib26 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2007.07.013 – reference: 17302184 - Recent Results Cancer Res. 2007;174:49-53 – reference: 15574769 - Cancer Res. 2004 Dec 1;64(23):8620-9 – reference: 18955434 - Genome Res. 2009 Jan;19(1):92-105 – reference: 19925378 - Acta Oncol. 2009;48(6):882-9 – reference: 12581018 - BJU Int. 2003 Feb;91(3):271-7 – reference: 23353719 - Asian J Androl. 2013 Mar;15(2):226-30 – reference: 15172979 - Cancer Res. 2004 Jun 1;64(11):3753-6 – reference: 19524507 - Cell. 2009 Jun 12;137(6):1032-46 – reference: 16018833 - Can J Urol. 2005 Jun;12 Suppl 2:42-7 – reference: 17349528 - Urol Oncol. 2007 Mar-Apr;25(2):134-40 – reference: 22251626 - Breast Cancer Res. 2012;14(1):R14 – reference: 11507082 - Cancer Res. 2001 Aug 15;61(16):6276-80 – reference: 18667687 - Endocr Relat Cancer. 2008 Dec;15(4):841-9 – reference: 20610543 - CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 – reference: 22155254 - Biochem Biophys Res Commun. 2012 Jan 6;417(1):371-5 – reference: 20418948 - PLoS One. 2010;5(4):e10147 – reference: 19074899 - Cancer Res. 2008 Dec 15;68(24):10307-14 – reference: 18381893 - Genes Dev. 2008 Apr 1;22(7):894-907 – reference: 20041405 - Hepatology. 2010 Mar;51(3):836-45 – reference: 20603000 - Cell. 2010 Jun 25;141(7):1195-207 – reference: 12767520 - Cancer Lett. 2003 Jun 10;195(2):127-37 – reference: 17898713 - Nature. 2007 Oct 11;449(7163):682-8 – reference: 20848182 - Breast Cancer Res Treat. 2011 Apr;126(3):687-94 – reference: 22972404 - Oncol Rep. 2012 Dec;28(6):2101-6 – reference: 22965940 - J Clin Endocrinol Metab. 2012 Nov;97(11):E2168-78 – reference: 17728006 - Lung Cancer. 2007 Dec;58(3):392-6 – reference: 23134218 - Cancer Biother Radiopharm. 2013 Mar;28(2):131-7 – reference: 18344688 - Cell Cycle. 2008 Mar 15;7(6):759-64 – reference: 15694866 - Trends Mol Med. 2005 Feb;11(2):52-5 |
SSID | ssj0023199 |
Score | 2.092387 |
Snippet | Reduced microRNA (miRNA) let-7a expression and the activation of insulin-like growth factor-1 receptor (IGF1R) signalling are both involved in prostate cancer... Reduced microRNA (miRNA) let-7a expression and the activation of insulin-like growth factor-1 receptor (IGF1R) signalling are both involved in prostate cancer... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 753 |
SubjectTerms | 3' Untranslated Regions Base Sequence Cell Line, Tumor DNA Primers Humans Male MicroRNAs - genetics Original Prostatic Neoplasms - genetics Prostatic Neoplasms - metabolism Prostatic Neoplasms - pathology Real-Time Polymerase Chain Reaction Receptor, IGF Type 1 - genetics RNA, Messenger - genetics |
Title | The miRNA let-7a1 inhibits the expression of insulin-like growth factor 1 receptor (IGF1R) in prostate cancer PC-3 cells |
URI | https://www.ncbi.nlm.nih.gov/pubmed/23974362 https://www.proquest.com/docview/1448240813 https://www.proquest.com/docview/1449279391 https://pubmed.ncbi.nlm.nih.gov/PMC3854054 |
Volume | 15 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9swED62FsZexn7PWxc06MM20Gpbsi09jbY06wYNJayQNyPL0uK2c7Imhf75u7OVtNnG3gw6kPB3uvt0Ot0B7KK9s-jpcp5a7Tl6PMerTKQ8Vw4tcu4TYSigfzLKj8_kt0k2CQG3RUirXNnEzlDXM0sx8j0k_orKcSXi8_wXp65RdLsaWmjch20qXUZaXUxuD1yi7x9J9Wtw8nQS3ufFQu2Zcyo6lIhPSm56pL9o5p_Zknfcz_AxPAq8ke33QD-Be659Cg9Ows34M7hBvNnPZjzaZ4gEL0zCmnbaVM1ywZDjMXcTMl5bNvMsZKDzy-bCsR94El9OWd95hyUMbaCb0-f7r1-GyfgDSrM5PQ5BWsosackVOz3kglHQf_EczoZH3w-PeeiqwC2e5XABhS4s8pzCpd5oaVScxVZleMyItS-Q3ylfaGtqa-OsSikLFLes98rppIprVYsXsNXOWvcKWB47I2PvnUTB3HrjdWVyX7jaSLSbeQQfV3-2tKHkOHW-uCy7q2-hSoShJBhKJSPYXQvP-0ob_xbbWUFUhu22KG-VI4J362HcKPQjTOtm152MTtEa6SSClz2i63lSZGUSXXkExQbWawEqwr050jbTrhi3UMR55ev_L-sNPKT1948Yd2BreXXt3iKbWVaDTmUHsH1wNDodD7qYwG-d6faT |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9QwDLfGkIAXxDdlA4I0JEAKa5t-pA8ITYPjju1OaNqke-vSNOEKo3fbdWL7p_Y3YvfjxgHibW-VYrVN7Ng_x44NsIH6TqOli7ivE8vR4hmehcLnkTSokSPrCUUH-sNR1D8IPo_D8QpcdHdhKK2y04m1os6nms7INxH4SyrH5Yn3s2NOXaMoutq10GjEYsec_0SXbf5u8AH5-9L3ex_3t_u87SrANfoyFcLJJNZo52PjW5UESrqhq2WIMNtNbIz4Rto40SrX2g0zn7IgUWStlSbxMjeXucD3XoPraHhdcvbi8aWDJ5p-lVQvByfrj9v7gK6Qm-obFTnyxFsZLFvAv2Dtn9mZv5m73h243eJUttUI1l1YMeU9uDFsI_H34Qzli_0o9kZbDDnPY-WxopwUWVHNGWJKZs7aDNuSTS1rM975UfHdsK_o-VcT1nT6YR5DnWtm9Phq8Knn7b1GajajyygIg5kmqTxhX7a5YBRkmD-AgytZ74ewWk5L8xhY5BoVuNaaAAkjbZVNMhXZ2OQqQD0dOfCmW9lUtyXOqdPGUVqH2oVMkQ0psSGVgQMbC-JZU9nj32TrHYvSdnvP00thdODFYhg3Ji2EKs30tKZJfNR-iefAo4aji-_4iAIDhA4OxEu8XhBQ0e_lkbKY1MW_hSSMHTz5_289h5v9_eFuujsY7azBLZpLc4FyHVark1PzFJFUlT2rxZfB4VXvl1-G6y9- |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+miRNA+let-7a1+inhibits+the+expression+of+insulin-like+growth+factor+1+receptor+%28IGF1R%29+in+prostate+cancer+PC-3+cells&rft.jtitle=Asian+journal+of+andrology&rft.au=Wang%2C+Li-na&rft.au=Chen%2C+Wei-wen&rft.au=Zhang%2C+Ju&rft.au=Li%2C+Chao-yang&rft.date=2013-11-01&rft.pub=Medknow+Publications+%26+Media+Pvt.+Ltd&rft.issn=1008-682X&rft.eissn=1745-7262&rft.volume=15&rft.issue=6&rft.spage=753&rft_id=info:doi/10.1038%2Faja.2013.84&rft.externalDocID=3116500401 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1008-682X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1008-682X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1008-682X&client=summon |